Document is current
Any future updates will be listed below
-
Authors
Fountoukidis, Georgios
Tina, Elisabet
Göthlin-Eremo, Anna
Ullenhag, Gustav
Valachis, Antonios
-
Funding
Funding for this research was provided by:
This study was supported by ALF funding from Region Örebro County (grant number OLL-1021286)
Örebro University
- License Information
-
More Information
Article History
Received: 19 March 2026
Accepted: 13 May 2026
First Online: 8 June 2026
Declarations
:
: Conflict of interest GU reports potential conflicts of interest in recent three years: Educational events and/or meetings arranged by MSD, BMS, Novartis, Astellas, Astrazeneca, Sanofi, Regeneron and Pierre Fabre. AV reports institutional consultancy fees (for educational purposes) from AstraZeneca, Daiichi Sankyo, Gilead, MSD, Lilly, Novartis and Pfizer. He reports institutional unrestricted grant from Roche and MSD unrelated to current study. All other authors declare no conflicts of interest.
